<DOC>
	<DOCNO>NCT00353080</DOCNO>
	<brief_summary>To confirm superiority 5 mg daily risedronate compare placebo maintain increase bone mass lumbar spine osteopenic postmenopausal woman To confirm efficacy 5 mg daily risedronate osteopenic postmenopausal woman maintain increase bone mass proximal femur decrease bone resorption To confirm general safety 5 mg daily risedronate compare placebo</brief_summary>
	<brief_title>Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Ambulatory , healthy postmenopausal woman Natural menopause 5 year last menstrual period surgical menopause 5 year surgery osteopenia ( lumbar spine T score 1 2.5 SD mean value normal young woman ) . With least one risk factor osteoporosis Women receive hormone replacement therapy ( estrogen and/or progestogen and/or androgen ) raloxifene within 3 month visit 2 calcitonin calcitriol within 4 week visit 2</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Prevention postmenopausal osteoporosis</keyword>
</DOC>